title: Dermatomyositis associated with thyroid cancer: a paraneoplastic syndrome?
authors.forename: Takao
authors.initials: T
authors.lastname: Nagashima
authors.forename: Sachiko
authors.initials: S
authors.lastname: Onishi
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Kamata
authors.forename: Seiji
authors.initials: S
authors.lastname: Minota
mesh_terms: D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D003882:Dermatomyositis / Q000150:complications* / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D010257:Paraneoplastic Syndromes / Q000150:complications*; D011239:Prednisolone / Q000627:therapeutic use; D020551:Pulse Therapy, Drug; D013964:Thyroid Neoplasms / Q000150:complications* / Q000473:pathology*; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone; D008775:Methylprednisolone